CancerCare

Counseling. Support Groups. Education. Financial Assistance.

Honoree Bios

 

Leon (Lonnie) O. Moulder, Jr. has served as Chief Executive Officer and as a member of the Board of Directors since co-founding TESARO in March 2010. From April 2009 to January 2010, Mr. Moulder served as Vice Chairman of the Board of Directors and President and Chief Executive Officer of Abraxis BioScience, Inc., a biotechnology company, and as president and Chief Executive Officer of its wholly owned operating subsidiary, Abraxis BioScience, LLC, and the Abraxis Oncology division. Before that, Mr. Moulder served as Vice Chairman and Executive Vice President of Eisai Corporation of North America, from January 2008 until January 2009, following Eisai Co. Ltd.'s acquisition of MGI PHARMA, a pharmaceutical company, in January 2008. Mr. Moulder served as President and Chief Executive Officer and as member of the Board of Directors of MGI PHARMA from May 2003 through January 2008. Mr. Moulder joined MGI PHARMA in September 1999 as Executive Vice President and was promoted to President and Chief Operating Officer in May 2002. Mr. Moulder earned a bachelor of science in pharmacy from Temple University and master of business administration from the University of Chicago. Mr. Moulder currently serves as chairman of the Board of Directors of Trevena, as a trustee of Temple University and is on the Board of the Fox Chase Cancer Center. He also served as a Director of Cubist Pharmaceuticals through the sale of the company in 2015.

 

Mary Lynne Hedley, Ph.D. has served as TESARO’s President and as a member of the Board of Directors since co-founding TESARO in March 2010. From July 2009 to February 2010, Dr. Hedley served as Executive Vice President of Operations and Chief Scientific Officer of Abraxis BioScience, a biotechnology company. Dr. Hedley served as Executive Vice President of Eisai Corporation of North America from January 2008 until July 2009, following the company's acquisition of MGI PHARMA in January 2008. Dr. Hedley served in various positions at MGI PHARMA from 2004 through its acquisition in January 2008, most recently as Executive Vice President and Chief Scientific Officer. Prior to that, Dr. Hedley co-founded and served as the President and Chief Executive Officer of ZYCOS, a biotechnology company, which was acquired by MGI PHARMA in 2004. Prior to co-founding Zycos, Dr. Hedley completed two consecutive postdoctoral fellowships at Harvard University and earned her bachelor of science degree in microbiology from Purdue University and her doctoral degree in immunology from the University of Texas, Southwestern Medical Center. She mentors undergraduate science students at Harvard University and Boston University and also serves on the Boards of Directors of bluebird bio, Millendo Therapeutics and Youville Place, an assisted living facility. She served on the Board of Directors for Receptos until its acquisition by Celgene.

 

Cornelia and Rob Spring are honored to receive CancerCare’s 2018 Help and Hope Award. Cornelia has been a member of CancerCare’s National Board since 2011 and with Rob served as Gala Committee Chairs in 2012 and 2013. Cornelia is a Managing Director at J.P. Morgan where she has spent her career in The Private Bank working with individuals and their families on their investments, banking and wealth planning needs. She is currently a senior marketer in J.P. Morgan’s Endowments & Foundations Group. Cornelia served on the board of Kents Hill School for many years and is a member of the American Council on Germany. Rob was a partner at Milbank, Tweed, Hadley & McCloy advising corporate clients on financings, infrastructure projects and private investments. Rob is a Managing Director of Gracie Square Capital. He is on the board of National Defense University and The Jamestown Foundation and involved with The Fletcher School of Law and Diplomacy. Cornelia and Rob have three sons, Huyette, Peter and Alexander and live in New York City.